CION Ameerpet
Cervical Cancer Types · Reviewed by CION Oncologists · NABH Accredited
Cervical Adenocarcinoma — The Glandular Type, Explained
Adenocarcinoma is the cervical cancer that begins in the glandular cells lining the cervical canal — the mucus-making cells inside the passage, rather than the flat cells on the outer surface. It is the second commonest cervical cancer after squamous cell carcinoma, and its share of cases has been rising in countries with long-established screening programmes, because cytology finds glandular disease less reliably than it finds squamous disease. The important thing to know at the outset is that adenocarcinoma is staged and treated on the same principles as the commoner type. What differs is how it is found, what the pathologist must look for, and how carefully the subtype has to be pinned down.
- Starts inside the canal — in the glandular lining, which is why a surface smear can miss it
- Same FIGO staging, same treatment principles — surgery for early disease, chemoradiation for locally advanced
- Subtype matters more here — WHO separates HPV-associated from HPV-independent glandular tumours
- Expert pathology first — slides reviewed before a treatment plan is agreed at the tumour board
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Where Cervical Adenocarcinoma Starts, and Why That Matters
The cervix has an outside and an inside. The outside, which a doctor can see through a speculum, is covered by flat squamous cells. The inside — the endocervical canal running up towards the womb — is lined by tall glandular cells whose job is to produce mucus. An adenocarcinoma is a cancer of those glandular cells. The prefix adeno simply means gland.
That single anatomical fact explains most of what is different about this diagnosis. A screening brush sweeps the outer cervix and the transformation zone very effectively, which is why precancerous squamous change is picked up so reliably. Glandular abnormality can sit higher up inside the canal, out of easy reach of the brush and out of sight at colposcopy. It can also be patchy rather than continuous. The consequence is not that screening is useless for adenocarcinoma — it plainly is not — but that a normal smear offers less reassurance about glandular disease than it does about squamous disease.
The commonest form remains firmly linked to persistent high-risk HPV, with HPV 18 featuring more prominently than it does in squamous cell carcinoma of the cervix. A minority of glandular tumours are not driven by HPV at all, and those are the ones that need the most careful pathological identification, because they are neither prevented by vaccination nor detected by HPV-based screening.
Did You Know? The 2020 WHO classification reorganised cervical glandular tumours around a single question — is this tumour driven by HPV or not? Endocervical adenocarcinomas are now reported as either HPV-associated or HPV-independent, the latter group including gastric-type, clear cell and mesonephric adenocarcinoma. The distinction is made using p16 immunohistochemistry and HPV testing, and it matters because the HPV-independent tumours are not preventable by vaccination and are not reliably picked up by HPV-based screening. Source: WHO Classification of Tumours, Female Genital Tumours, 5th edition (2020).
The Glandular Subtypes Your Report May Name
Unlike the squamous subtypes, some of these genuinely change how the tumour is expected to behave — which is why the exact wording on a glandular report deserves close reading.
Commonest
HPV-Associated Adenocarcinoma
Formerly called the usual endocervical type, this accounts for the large majority of cervical adenocarcinomas. It is p16-positive, HPV-driven, and preceded by a recognised precancerous stage. It responds to the standard cervical cancer treatment pathway.
Precancer
Adenocarcinoma In Situ (AIS)
Abnormal glandular cells confined to the lining, with no invasion. This is not cancer. Because it can be patchy and extend high into the canal, it is usually treated by removing a cylinder of the canal and checking that the margins are clear.
HPV-independent
Gastric-Type Adenocarcinoma
An uncommon type whose cells resemble stomach lining. It is not HPV-driven, is p16-negative, often produces a striking watery discharge, and tends to present at a more advanced stage. Recognising it changes both the surveillance plan and the counselling.
HPV-independent
Clear Cell Adenocarcinoma
A rare tumour with distinctive clear cytoplasm, historically linked to in-utero diethylstilbestrol exposure but now seen mostly without it. It is covered in more detail on our clear cell cervical cancer page and is managed by the same stage-based principles.
HPV-independent
Mesonephric Adenocarcinoma
Very rare, arising from embryonic remnants deep in the cervical wall. It is easily mistaken for other glandular tumours on a small biopsy, which is exactly why an expert glandular pathology opinion is worth obtaining before treatment begins.
Pattern grading
Silva Pattern A, B or C
For HPV-associated tumours, pathologists may describe the growth pattern rather than a numerical grade. Pattern A describes well-demarcated glands without destructive invasion; pattern C describes diffusely infiltrative growth. It informs how aggressively lymph nodes need to be assessed.
Some tumours contain both glandular and squamous cancer within the same specimen — those are reported as adenosquamous and mixed cervical cancers and are covered separately.
Why Screening Finds Glandular Disease Less Easily
Women diagnosed with adenocarcinoma frequently ask the same question: I had my smears, so how was this missed? It is a fair question, and there is a real answer rather than a defensive one.
- The abnormality is out of reach. Cytology samples the surface. Glandular precancer can sit centimetres up the canal, where the brush does not reach and the colposcope cannot see.
- It is often multifocal. Squamous precancer usually forms one continuous area. Glandular precancer can appear as separate patches with normal lining in between, so a single sample can land on healthy tissue.
- Glandular cells are harder to interpret. Reactive and repair changes in glandular cells can look worrying, and genuinely abnormal cells can look bland. This is one of the more demanding calls in cervical cytology.
- HPV testing helps here. Because these tumours are usually HPV-driven, a primary HPV test flags women who need a closer look even when their cells appear normal — one of the reasons WHO now recommends HPV-based testing as the preferred screening approach.
- A watery discharge is a symptom worth reporting. Persistent watery vaginal discharge, with or without bleeding, is a recognised presentation of glandular cervical disease and deserves an examination rather than repeated courses of treatment for infection.
None of this means screening failed you. Screening substantially reduces adenocarcinoma too — it simply reduces it less than it reduces squamous cancer. What follows practically is that a glandular abnormality on a smear should never be watched and repeated; it needs endocervical sampling, and often a cone biopsy, because only a larger specimen shows the pathologist the depth, the growth pattern and the margins across the whole lesion.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get the Subtype Confirmed Before the Plan Is Made
With glandular tumours, the precise diagnosis is worth an extra week of pathology. Bring your slides or your report to any of CION's 7 NABH-accredited Hyderabad locations.
Staging and Work-Up for a Glandular Cervical Cancer
Adenocarcinoma of the cervix uses the same FIGO 2018 staging system as every other cervical carcinoma. There is no separate glandular staging system, and no separate stage numbering. What differs slightly is the emphasis at each step.
Step 1 — establishing the true extent of the lesion
Because glandular disease extends along the canal rather than spreading outwards over the surface, a small punch biopsy may understate it. A cone biopsy or loop excision that includes the canal is often needed so the pathologist can measure invasion properly and report the margins.
Step 2 — MRI of the pelvis
MRI shows tumour size, how deeply it has grown into the cervical wall, and whether it has reached the tissue beside the cervix or the upper vagina. For a tumour growing lengthwise inside the canal, this is often more informative than what an examining finger can feel.
Step 3 — PET-CT for nodes and distant disease
Under the FIGO 2018 revision, lymph node involvement is part of the stage itself, so nodal assessment is not optional. PET-CT is the usual tool for looking at pelvic and para-aortic nodes and for excluding disease elsewhere before a curative plan is set.
Step 4 — confirming the subtype, and testing where it is unclear
p16 and HPV testing separate HPV-associated tumours from the HPV-independent group. Where an adenocarcinoma might have come from the womb lining rather than the cervix, additional stains are used, since the two are staged and treated differently.
Step 5 — the tumour board decision
The complete picture goes to a multidisciplinary meeting before anything is offered. NCCN and ESMO guidance both place adenocarcinoma on the same treatment pathway as squamous carcinoma at equivalent stage, so the discussion is about stage, size, nodes and your own priorities — including fertility, where that is relevant.
Glandular Subtypes at a Glance
A quick reference for the words most often seen on an endocervical pathology report. This is a guide to what each term describes, not a prediction about any individual tumour.
| Term on the report | HPV-driven? | What it tells your team |
|---|---|---|
| Adenocarcinoma in situ (AIS) | Yes | Precancer, not cancer. Excision of the canal with clear margins is usually all that is required |
| HPV-associated adenocarcinoma | Yes, p16-positive | The standard glandular cancer; treated on the usual stage-based pathway |
| Gastric-type adenocarcinoma | No, p16-negative | Not screen-detected or vaccine-preventable; needs close staging and careful counselling |
| Clear cell adenocarcinoma | No | Rare; stage-based treatment, with expert pathology confirmation worthwhile |
| Mesonephric adenocarcinoma | No | Very rare and easily misread on a small biopsy; a second pathology opinion is valuable |
| Silva pattern A / B / C | Applies to HPV-associated tumours | Describes the growth pattern; helps decide how thoroughly lymph nodes must be assessed |
| Endometrioid, of cervical origin | Variable | Prompts extra stains to confirm the tumour started in the cervix and not in the womb lining |
If any of these terms appears on your report and has not been explained, ask. For the broader context of how cervical cancer develops, screening works and prevention fits together, start from the cervical cancer overview.
Did You Know? WHO now recommends an HPV DNA test as the preferred primary screening method for cervical cancer, in place of cytology alone. For glandular disease this matters more than it does for squamous disease: a virus test does not depend on catching abnormal cells from a lesion sitting high inside the canal, so it flags women who need endocervical assessment even when their cytology reads as normal. Source: WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition (2021).
How Cervical Adenocarcinoma Is Treated
The treatment framework is the same as for the commoner squamous type. Where adenocarcinoma differs is in the detail of surgical planning, because a tumour that spreads lengthwise inside the canal has to be removed with that geometry in mind.
Precancer (AIS) — excision, with the margins doing the work
A cone or cylindrical excision of the canal, examined to confirm the margins are clear. Because AIS can be patchy, a positive margin is taken seriously and usually means further excision. Follow-up with HPV testing is important afterwards, and a hysterectomy may be considered once a woman's family is complete.
Early-stage disease — surgery, with node assessment
Removal of the cervix and surrounding tissue with assessment of the pelvic lymph nodes. Fertility-sparing surgery can be considered in selected small tumours, though the assessment is more cautious for glandular disease than for squamous, precisely because the extent inside the canal is harder to judge.
Locally advanced — chemoradiation with brachytherapy
External radiation to the pelvis given alongside platinum-based chemotherapy, followed by brachytherapy. NCCN, FIGO and ESMO all treat brachytherapy as an essential component of curative treatment at this stage, and adenocarcinoma is treated on the same basis as squamous carcinoma of the same stage.
Advanced or recurrent — systemic treatment, guided by testing
Chemotherapy remains the backbone, with targeted therapy and checkpoint immunotherapy considered on the basis of tumour testing, including PD-L1 status. Specific regimens are individual decisions and are set out on our cervical cancer treatment in Hyderabad page rather than here.
Women often ask whether the glandular type carries a worse outlook. Stage for stage the difference is modest, and it is heavily outweighed by how early the cancer is found and whether the planned treatment is completed on schedule. That is the part your team can influence, and it is where attention belongs.
Why Glandular Cervical Cancers Are Reviewed Carefully at CION
This is a diagnosis where the pathology wording changes the plan. It should be settled before treatment, not after.
Pathology review before treatment
Tumour board for every diagnosis
Cone biopsy and colposcopy in-house
MRI and PET-CT under one roof
Fertility discussed before surgery
45-minute detailed consultation
7 NABH-accredited Hyderabad locations
EMI facility & insurance accepted
4.8 / 5 Google rating
Take The Next Step
Ask About the Subtype, Not Just the Stage
With glandular cervical cancer, the two questions that matter most are what exactly the pathologist saw and how far it reaches. Both can be answered in one appointment.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Cervical Adenocarcinoma — Frequently Asked Questions
What is cervical adenocarcinoma and how is it different from the squamous type?
Cervical adenocarcinoma is a cancer of the mucus-producing glandular cells that line the cervical canal, whereas squamous cell carcinoma arises from the flat cells covering the outer cervix. It is the second commonest type of cervical cancer. The two are staged with the same FIGO system and treated on the same principles — surgery for early disease, chemoradiation with brachytherapy for locally advanced disease. The real differences are practical: glandular disease sits higher inside the canal, which makes it harder to sample and harder to see at colposcopy, and its subtypes need more careful pathological identification.
Why can a Pap smear miss adenocarcinoma of the cervix?
A cervical smear samples cells from the surface of the cervix and the transformation zone. Glandular abnormality can arise well above that, inside the endocervical canal, where the sampling brush may not reach and the colposcope cannot see. Glandular precancer is also often patchy rather than continuous, so a sample can land on normal lining between abnormal areas, and glandular cells are genuinely more difficult to interpret under the microscope than squamous cells. This is one reason WHO now recommends HPV testing as the preferred primary screening method: a virus test does not depend on catching abnormal cells from a lesion that sits out of reach.
What does adenocarcinoma in situ (AIS) of the cervix mean?
Adenocarcinoma in situ means abnormal glandular cells are confined to the lining of the cervical canal and have not invaded the tissue beneath. It is a precancer, not a cancer, and it is treatable. Because AIS can extend high into the canal and can be multifocal, it is usually managed by removing a cylinder of the canal — a cone or loop excision — and checking that the cut edges are free of abnormal cells. A positive margin generally means further excision rather than observation. Careful follow-up with HPV testing is important afterwards, and some women choose a hysterectomy once their family is complete.
Is gastric-type cervical adenocarcinoma linked to HPV?
No. Gastric-type adenocarcinoma is one of the HPV-independent glandular tumours recognised in the 2020 WHO classification, along with clear cell and mesonephric adenocarcinoma. Its cells resemble the lining of the stomach, it is typically p16-negative, and it often produces a marked watery vaginal discharge. Because it is not HPV-driven, it is not prevented by vaccination and is not reliably flagged by HPV-based screening, which is part of why it tends to be diagnosed at a more advanced stage. If your report uses this term, it is worth confirming the diagnosis with expert glandular pathology review before treatment is finalised.
Does having adenocarcinoma change my treatment compared with the commoner type?
The framework is the same. FIGO stage decides the pathway, and at each stage adenocarcinoma is treated on the same principles as squamous carcinoma — surgery with lymph node assessment for early disease, chemoradiation followed by brachytherapy for locally advanced disease, systemic treatment for advanced or recurrent disease. What tends to differ is the surgical planning, because a tumour growing lengthwise inside the canal has to be removed with that geometry in mind, and the threshold for fertility-sparing surgery is assessed more cautiously. Your tumour board will weigh stage, tumour size, node status and your own priorities together.
Medical disclaimer: This page is general health information, reviewed by a CION oncologist. It is not a diagnosis, a stage or a treatment recommendation, and it cannot replace review of your own pathology and imaging by a specialist. Please discuss your report with your treating team before making any decision about treatment.